Literature DB >> 6129147

Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice.

P Consroe, M A Benedito, J R Leite, E A Carlini, R Mechoulam.   

Abstract

In mice, running, clonic and tonic convulsions and lethality were assessed following transcorneal (electroshock) current or convulsant drugs, each administered alone and after cannabidiol (CBD) pretreatment. CBD prevented tonic convulsions caused by a convulsant current (CC) 99.99, and by the convulsant dose (CD) 99.99 values of gamma-aminobutyric acid (GABA) inhibitors, 3-mercaptoproprionic acid (3MPA), picrotoxin (PIC), isonicotinic acid hydrazine (INH), pentylenetetrazol (PTZ) and bicuculline (BIC). Rankorder potencies, based on the antitonic ED50 of CBD, were: 3MPA greater than PIC = current = PTZ = BIC. Further, CBD prevented 3MPA-induced lethality, but failed to prevent the occurrence of the other behavioral endpoints of the above treatments. CBD also failed to prevent convulsions and lethality caused by the CD 99.99 of strychnine, a glycine antagonist. The differential effects of CBD suggest that the cannabinoid acts to inhibit seizure spread in the CNS by an action on GABA, but not glycine, mechanisms.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6129147     DOI: 10.1016/0014-2999(82)90264-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  38 in total

1.  Marijuana use and the risk of new onset seizures.

Authors:  J C Brust; S K Ng; A W Hauser; M Susser
Journal:  Trans Am Clin Climatol Assoc       Date:  1992

Review 2.  [The endogenous cannabinoid system. Therapeutic implications for neurologic and psychiatric disorders].

Authors:  U Schneider; J Seifert; M Karst; J Schlimme; K Cimander; K R Müller-Vahl
Journal:  Nervenarzt       Date:  2005-09       Impact factor: 1.214

Review 3.  Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.

Authors:  Orrin Devinsky; Maria Roberta Cilio; Helen Cross; Javier Fernandez-Ruiz; Jacqueline French; Charlotte Hill; Russell Katz; Vincenzo Di Marzo; Didier Jutras-Aswad; William George Notcutt; Jose Martinez-Orgado; Philip J Robson; Brian G Rohrback; Elizabeth Thiele; Benjamin Whalley; Daniel Friedman
Journal:  Epilepsia       Date:  2014-05-22       Impact factor: 5.864

Review 4.  Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection.

Authors:  Evan C Rosenberg; Pabitra H Patra; Benjamin J Whalley
Journal:  Epilepsy Behav       Date:  2017-02-09       Impact factor: 2.937

Review 5.  Marijuana Use in Epilepsy: The Myth and the Reality.

Authors:  Kamil Detyniecki; Lawrence Hirsch
Journal:  Curr Neurol Neurosci Rep       Date:  2015-10       Impact factor: 5.081

6.  Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo.

Authors:  Nicholas A Jones; Andrew J Hill; Imogen Smith; Sarah A Bevan; Claire M Williams; Benjamin J Whalley; Gary J Stephens
Journal:  J Pharmacol Exp Ther       Date:  2009-11-11       Impact factor: 4.030

Review 7.  Cannabinoids and Epilepsy.

Authors:  Evan C Rosenberg; Richard W Tsien; Benjamin J Whalley; Orrin Devinsky
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

Review 8.  Prospects of Cannabidiol for Easing Status Epilepticus-Induced Epileptogenesis and Related Comorbidities.

Authors:  Dinesh Upadhya; Olagide W Castro; Raghavendra Upadhya; Ashok K Shetty
Journal:  Mol Neurobiol       Date:  2018-01-25       Impact factor: 5.590

9.  Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy.

Authors:  Brenda E Porter; Catherine Jacobson
Journal:  Epilepsy Behav       Date:  2013-12       Impact factor: 2.937

10.  Evaluation of interactions between cannabinoid compounds and diazepam in electroshock-induced seizure model in mice.

Authors:  Nima Naderi; Farzad Aziz Ahari; Bijan Shafaghi; Azadeh Hosseini Najarkolaei; Fereshteh Motamedi
Journal:  J Neural Transm (Vienna)       Date:  2008-06-25       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.